Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Hormones – e.g. – prolactin – thymosin – growth factors – etc.
Reexamination Certificate
2011-08-30
2011-08-30
Ha, Julie (Department: 1654)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Hormones, e.g., prolactin, thymosin, growth factors, etc.
C530S330000, C530S333000, C564S254000, C570S113000
Reexamination Certificate
active
08008456
ABSTRACT:
Non-natural amino acids and polypeptides with non-natural amino acids are disclosed. Further, polypeptides with non-natural amino acids that are subject to post-translational modification are disclosed. Additionally, methods of making, purifying, and using non-natural amino acids and polypeptides with non-natural amino acids are disclosed. The non-natural amino acids, by themselves or as part of a polypeptide, can include a wide range of possible functionalities, but typically have at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Uses for the non-natural amino acids and polypeptides with non-natural amino acids include diagnostic, therapeutic, and various biotechnology uses.
REFERENCES:
patent: 3859273 (1975-01-01), Beregi et al.
patent: 4272432 (1981-06-01), Yardley et al.
patent: 4680311 (1987-07-01), Watanabe et al.
patent: 5364840 (1994-11-01), Basava et al.
patent: 5484771 (1996-01-01), Beaulieu et al.
patent: 6337191 (2002-01-01), Swartz et al.
patent: 6344483 (2002-02-01), Hallinan et al.
patent: 6448281 (2002-09-01), Beaulieu et al.
patent: 6449281 (2002-09-01), Smith
patent: 6455550 (2002-09-01), Chen
patent: 6492421 (2002-12-01), Thorsett et al.
patent: 6608183 (2003-08-01), Cox, III
patent: 6608196 (2003-08-01), Wang et al.
patent: 6900218 (2005-05-01), Wang et al.
patent: 7056942 (2006-06-01), Hildesheim et al.
patent: 7332571 (2008-02-01), Miao et al.
patent: 7385028 (2008-06-01), Miao et al.
patent: 7638491 (2009-12-01), Miao et al.
patent: 2002/0065418 (2002-05-01), Beaulieu et al.
patent: 2002/0081660 (2002-06-01), Swartz et al.
patent: 2003/0072746 (2003-04-01), Miller
patent: 2003/0082575 (2003-05-01), Schultz et al.
patent: 2003/0108885 (2003-06-01), Schultz et al.
patent: 2006/0217289 (2006-09-01), Miao et al.
patent: 2008/0118464 (2008-05-01), Miao et al.
patent: 2008/0139793 (2008-06-01), Tian et al.
patent: 2008/0153979 (2008-06-01), Miao et al.
patent: 2008/0154058 (2008-06-01), Tian et al.
patent: 2008/0177027 (2008-07-01), Miao et al.
patent: 2008/0177038 (2008-07-01), Miao et al.
patent: 2008/0182968 (2008-07-01), Miao et al.
patent: 2008/0187491 (2008-08-01), Miao et al.
patent: 2008/0194459 (2008-08-01), Miao et al.
patent: 2008/0213840 (2008-09-01), Miao et al.
patent: 2008/0268518 (2008-10-01), Miao et al.
patent: 2008/0268519 (2008-10-01), Miao et al.
patent: 2009/0111147 (2009-04-01), Miao et al.
patent: 2009/0123968 (2009-05-01), Miao et al.
patent: 2110543 (1994-06-01), None
patent: 0605963 (1994-07-01), None
patent: WO-90-05785 (1990-05-01), None
patent: WO 96/41813 (1996-12-01), None
patent: WO-00-55353 (2000-09-01), None
patent: WO-03-044056 (2003-05-01), None
patent: WO-2004-035743 (2004-04-01), None
patent: WO-2004-094593 (2004-11-01), None
patent: WO-2006-069246 (2006-06-01), None
patent: WO-2006-069246 (2006-06-01), None
patent: WO-2007-056448 (2007-05-01), None
patent: WO-2007-056448 (2007-05-01), None
patent: WO-2007-070659 (2007-06-01), None
patent: WO-2007-070659 (2007-06-01), None
patent: WO-2007-079130 (2007-07-01), None
patent: WO-2007-079130 (2007-07-01), None
Definition of derivative and analog from http://cancerweb.ncl.ac.uk/cgi-bin/omd?query=derivative, pp. 1-5. Accessed Jul. 7, 2005.
Definition of moiety from http://dictionary.reference.com/browse/moiety, pp. 1-3. Accessed Aug. 26, 2010.
Sequence of fibroblast growth factor (Homo sapien) from NCBI GenBank, p. 1. Accessed Oct. 28, 2010.
Alpha Interferon, GenBank Accession No. AAA37889, pp. 1-2. Accessed Jan. 16, 2009.
Auerback, R. et al., “Angiogenesis assays: Problems and pitfalls,” Cancer and Metastasis Reviews 19:167-172 (2000).
Basu, B. et al., “Catalytic transfer reduction of conjugated alkenes and an imine using polymer-supported formates,” Tetrahedron Ltrs. 44:8931-8934 (2003).
Berendsen, H., “A Glimpse of hte Holy Grail?”, Science 282:642-643 (1998).
Beta Interferon, GenBank Accession No. NP—002167, pp. 1-3. Accessed Jan. 16, 2009.
Bradley, C.M. and Barrick, D., “Limits of Cooperativity in a Structurally modular protein: Response of the Notch ANkyrin Domain to Analogous Alanine Substitutions in Each Repeat,” J. Mol. Biol. 324:373-386 (2002).
Brannigan, J.A. and Wilkinson, A.J., “Protein engineering 20 years on,” Nature 3:964-970 (2002).
Buckel, P., Recombinant Protein Drugs: Milestones in Drug Therapy, Bitkhauser Verlag, eds.,2001, Preface and pp. 191-197.
Clinical Aspects of Cancer from Merck Manual, pp. 1-4. Accessed Feb. 20, 2008.
Dementia including Alzheimer's Disease from the Merck Manual, Apr. 30, 2007.
Designing Custom Peptides from SIGMA Genosys, pp. 1-2. Accessed Dec. 16, 2004.
Disorders from the Merck Manual, Apr. 30, 2007.
Diseases from the Merck Manual, Apr. 30, 2007.
Epidermal Growth Factor, GenBank Accession No. CAA34902, p. 1, Accessed Jan. 16, 2009.
Erythropoietin, GenBank Accession No. CAA26095, pp. 1-2. Accessed Jan. 16, 2009.
EP 085855215.9 Search Report dated Jan. 12, 2009.
Fibroblast Growth Hormone, GenBank Accession No. CAA41788, pp. 1-2. Accessed Jan. 16, 2009.
Gura, T., “Systems for Identifying New Drugs Are Often Faulty,” Cancer Models, Science 278:1041-1042 (1997).
Human Growth Hormone, GenBank Accession No. AAA72260, p. 1. Accessed Jan. 16, 2009.
Introduction to Cancer from Merck Manual, p. 1. Accessed Mar. 5, 2008.
Jain, R.K., “Barriers to Drug Delivery in Solid Tumors,” Scientific American, Jul. 1994, 58-65.
Jullian, V. et al., “Synthesis of New Photoactivatable Phenylalanine Analogues and Their Incorporation into a Model Peptide—Phenylseleno Derivatives as Precursors of α,β-Unsaturated Ketones in Peptide Synthesis,” Eur. J. Org. Chem., 2002, 1677-1684.
Kinoshita, K. et al., “Studies on Antibiotics and Related Substances. XXIX. Synthesis of 2-Acetamido-5-oxo-6-heptenoic Acid and 2-Acetamido-4-oxo-5-hexenoic Acid,” Bull. Chem Soc. Japan 40:926-931 (1967).
Mattson, M.P., “Pathways towards and away from Alzheimer's disease,” Nature 430:631-639 (2004).
Ngo, J.T. et al., “Computational complexity, protein structure prediction and the Levinthal Paradox,” from The Protein Folding Problem and Tertiary Structure Prediction, K. Merc. Jr. and S. Le Grand, Editors, 1994, pp. 491-495.
Primrose, S., “Principles of Gene Manipulation and Genomics,” Blackwell Publishing, 2006, Chapter 8, http://www.blackwellpublishing.com/contents.asp?ref=9781405135443&site=1.
Rudinger, J., “Characteristics of amino acids as components of a peptide hormone sequence,” from Peptide Hormones, J.A. Parsons, MA, BM, B.Ch., University Park Press, Jun. 1976.
Schinzel, R. and Drueckes, P., “The phosphate recognition site ofEscherichia colimaltodextrin phosphorylase,” Federation of Eur. Biochem. Soc., Jul. 1991, 286(1,2): 125-128).
Short Stature from http://www.emedicine.com/PED/topic2087.htm pp. 1-21. Accessed Nov. 30, 2008.
Skolnick, J. and Fetrow, J.S., “From genes to protein structure and function: novel applications of computational approaches in the genomic era,” Trends Biotech. 18:34-39 (2000).
Sriram, S. and Steiner, I., “Experimental Allergic Encephalomyelitis: A Misleading Model of Multiple Sclerosis,” Annals Neurology 58:939-945 (2005).
Steinman, L. and Zamvil, S.S., “How to Successfully Apply Animal Studies in Experimental Allergic Encephalomyelitis to Research on Multiple Sclerosis,” Annals Neurology 60:12-21 (2006).
Tomlinson, I.M., “Ankyrin repeats generate high-affinity protein binders with biophysical properties that may favor therapeutic applications,” Nature Biotech. 22(5):521-522 (2004).
Voet, D. and Voet, J.G., Biochemistry, 2ndEdition, John Wiley & Sons, Inc., 1995, pp. 235-241.
Willans, C.E. et al., Ligand-free palladium catalyzed Heck reaction of methyl 2-acetamido acrylate and aryl bromides as key step in the synthesis of enantiopure substituted phenylalanines, J. Organometallic Chem. 687:494-497 (2003).
U.S. Appl. No. 11/925,743, filed Oct. 26, 2007.
Driver Russell
Liu Junjie
Miao Zhenwei
Norman Thea
AMBRX, Inc.
Ha Julie
Wilson Sonsini Goodrich & Rosati
LandOfFree
Compositions containing, methods involving, and uses of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions containing, methods involving, and uses of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions containing, methods involving, and uses of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2648346